Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

PURPOSE: To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. METHODS: PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly...

Descripción completa

Detalles Bibliográficos
Autores principales: Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Webb, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799252/
https://www.ncbi.nlm.nih.gov/pubmed/26603536
http://dx.doi.org/10.1007/s11102-015-0693-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799252/
https://www.ncbi.nlm.nih.gov/pubmed/26603536
http://dx.doi.org/10.1007/s11102-015-0693-y

Ejemplares similares